| Renal cell carcinoma (RCC): fatter is better? A review on the role of obesity in RCC F Turco, M Tucci, RF Di Stefano, A Samuelly, M Bungaro, M Audisio, ... Endocrine-related cancer 28 (7), R207-R216, 2021 | 33 | 2021 |
| Therapeutic sequencing in advanced renal cell carcinoma: How to choose considering clinical and biological factors MD Delcuratolo, M Tucci, F Turco, RF Di Stefano, A Ungaro, M Audisio, ... Critical Reviews in Oncology/Hematology 181, 103881, 2023 | 9 | 2023 |
| Are tyrosine kinase inhibitors an effective treatment in testicular metastases from kidney cancer? Case report F Turco, M Tucci, RF Di Stefano, A Samuelly, M Bungaro, E Bollito, ... Tumori Journal 107 (6), NP149-NP154, 2021 | 5 | 2021 |
| Prognostic role of the duration of response to androgen deprivation therapy in patients with metastatic castration resistant prostate cancer treated with enzalutamide or … RF Di Stefano, M Tucci, F Turco, A Samuelly, M Bungaro, C Pisano, ... Prostate Cancer and Prostatic Diseases 24 (3), 812-825, 2021 | 5 | 2021 |
| Prognostic role of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with metastatic castration resistant prostate cancer treated with abiraterone or … C Pisano, M Tucci, DIS RF, F Turco, A Samuelly, M Bungaro, F Vignani, ... Minerva Urology and Nephrology 73 (6), 803-814, 2021 | 5 | 2021 |
| 48 h for femur fracture treatment: are we choosing the wrong quality index? A Aprato, A Casiraghi, G Pesenti, M Bechis, A Samuelly, C Galante, ... Journal of Orthopaedics and Traumatology 20, 1-5, 2019 | 5 | 2019 |
| Navigating the ICI Combination Treatment Journey: Patterns of Response and Progression to First-Line ICI-Based Combination Treatment in Metastatic Renal Cell Carcinoma A Samuelly, RF Di Stefano, F Turco, MD Delcuratolo, C Pisano, I Saporita, ... Journal of Clinical Medicine 13 (2), 307, 2024 | 2 | 2024 |
| Role of radium-223 discontinuation due to adverse events in castration-resistant prostate cancer patients. A retrospective monocentric analysis F Turco, M Tucci, T Angusti, A Parente, RF Di Stefano, S Urban, C Pisano, ... Tumori Journal 109 (2), 233-243, 2023 | 2 | 2023 |
| Development and Validation of Prognostic Model for Metastatic Castration-Resistant Prostate Cancer Patients Treated With First-Line Abiraterone or Enzalutamide O Caffo, U Basso, C Cattrini, P Ermacora, M Maruzzo, M Alberti, C Anesi, ... Clinical Genitourinary Cancer 23 (1), 102265, 2025 | | 2025 |
| Comparison of NRS-2002 and MST nutritional screening and correlation with quality of life items in lung cancer patients (REAL-TIME observation study) S Carnio, O Cantale, I Capizzi, I Stura, A Nepote, A Samuelly, G Bernardi, ... | | 2024 |
| Outcomes of post-progression therapies in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) progressing after docetaxel (DOC): Real-world data from an … O Caffo, M Maruzzo, A Samuelly, G Facchini, E Zanardi, M Nicodemo, ... Journal of Clinical Oncology 41 (6_suppl), 171-171, 2023 | | 2023 |
| Minerva Urology and Nephrology 2022 December; 74 (6): 703-13 T ANGUSTI, RF DI STEFANO, A PARENTE, M BUNGARO, F TURCO, ... Minerva 74, 2022 | | 2022 |
| 1444P Cancer diagnosis communication: The perspective of oncologists, patients and caregivers C Paratore, MVP Parravicini, O Cantale, F Carfì, C Zichi, T Gamba, ... Annals of Oncology 33, S1203, 2022 | | 2022 |
| Prognostic factors in metastatic castration resistant prostate cancer patients treated with radium-223: a retrospective study. T Angusti, DIS RF, A Parente, M Bungaro, F Turco, A Samuelly, C Pisano, ... Minerva Urology and Nephrology 74 (6), 703-713, 2022 | | 2022 |
| Minerva Urology and Nephrology 2021 December; 73 (6): 803-14 C PISANO, M TUCCI, RF DI STEFANO, F TURCO, A SAMUELLY, ... Minerva 73, 2021 | | 2021 |
